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Abstract
Cystic Fibrosis (CF) is the most frequent recessive disease of Caucasian patients. Association with other diseases or
syndromes has previously been reported. Co-morbidity may be a challenge for clinicians, who have to face more
severe problems.
We have described a CF infant, F508del homozygote, diagnosed by neonatal screening, who also had a
chromosome 18q terminal deletion [del (18)(q22-qter)]. Some clinical features of the 18q deletion: e.g., cardiopathy,
gastro-oesophageal reflux and severe muscular hypotonia, worsened the CF clinical picture and his quality of life,
with repeated pulmonary exacerbations and failure to thrive in the first six months of life. The treatment strategy
was chosen following an accurate multi-disciplinary team study of overlapping chromosome syndrome and CF
symptoms. The use of a gastrostomy device for enteral nutrition together with a new device (Ez-PAP) for chest
physiotherapy led to normal growth, a notably reduced hospitalization rate and improved quality of life.
This case shows how co-morbidities worsening the clinical course of a “complicated patient” can be faced thanks
to unconventional therapies that represent a challenge for clinicians.
Background
Cystic fibrosis (CF; MIM #219700) is the most common
autosomal recessive disorder among the Caucasian
population, there being 1:25 carriers and an incidence of
1:2500-1:4400 [1,2].
CF is caused by mutations in the CFTR gene (7q31.2)
(MIM #602421). First cloned in 1989, this encodes a
trans-membrane ATP-binding cassette protein functioning
as an ion channel, which regulates chloride flow on the
apical membrane of epithelial cells [3]. Classical CF clinical
symptoms are: recurrent respiratory infections, nasal poly-
posis, bronchiectasis, exocrine pancreatic insufficiency and
male infertility [3].
Several patients have been reported to be affected by
CF in association with different diseases or syndromes
[4-8]. Clinical features of the genetic syndrome together
with CF manifestations create a chimeric disorder
requiring a focused therapeutic approach.
Here, we would like to add observations of an addi-
tional CF patient with another complicating disease.
This is the case of a CF infant with a chromosome 18q
deletion (whose incidence is 1/40.000 newborns). No
patient has so far been reported to be affected by both
18q- syndrome and Cystic Fibrosis. The estimated prob-
ability of finding both syndromes in a single patient is
1/120,000,000. The co-existing pathologies led to a tar-
geted therapeutic choice, which we have presented and
discussed.
Case Presentation
RB, male, aged 2, is the second child born from a couple
of Albanian non-consanguineous and healthy parents.
He was born after 36 weeks of uncomplicated gestation.
The newborn screening was positive for Cystic Fibrosis,
with hyper-trypsinogenemia (167.47 ng/ml; cut off 70
ng/ml) and identification of F508del homozygosis.
At birth, several dysmorphisms were noted: i.e., bilat-
eral cryptorchidism, bilateral inguinal hernias, unilateral
simian crease, naevus flammeus in fronto-orbital region,
congenital cardiopathy (inter-atrial defect), and hypoto-
nia. Standard karyotype performed on peripheral blood
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probe revealed the chromosome 18q22-qter deletion.
The parent’s karyotype were respectively 46,XX
(mother) and 46,XY (father); no cryptic 18q deletion
was found by the FISH analysis.
The infant was referred to the Regional Support CF
Centre at the Paediatric Department of Brescia (third
level hospital) to undergo the follow-up programme for
positive screening infant. Sweat test result confirmed CF
diagnosis (NaCl value was 108 mEq/l). Both parents
were found to be carriers of the F508del mutation, the
commonest worldwide mutation (66% of patient alleles).
No other family member was affected by the disease.
Our CF clinic took charge of the child. In addition to
the previously reported clinical features, the patient had
the following characteristics (Figure 1): wide spaced
front, sparse thin hair, deep set eyes, strabismus, mid-
face hypoplasia, long philtrum, thin upper lip, retrogna-
tia, dysmorphic low-set ears, tapered digits, proximal
thumb, overlapping second and third toe, persistent
hypotonia, EEG anomalies and psychomotor delay. Uni-
lateral mammary cystic neo-formations were also
detected.
The pancreatic status was insufficient (faecal elastase
values < 15 μg/g; severe steatorrhea, assessed by steato-
crit > 30%) and, growth was under the 10
th percentile
for length and < 3
rd for weight (Figure 2). Weight/
Length (W/L) ratio was < 3
rd centile (data not shown).
The cardiopathy the child presents is an inter-atrial
defect, ostium secundum type, with left-right shunt and
pulmonary hypertension. A marked and diffuse hypoto-
nia, with a severe delay in psychoneural development
were also evident.
The standard CF management was started, with pan-
creatic enzyme supplementation, daily chest physiother-
apy by means of PEP-mask, antibiotic therapy when
needed as well as salt and vitamin supplementation. For
the cardiopathy he received furosemide and continuous
oxygen supplementation, moreover Palivizumab was
administered monthly from months 2 to 6 [9].
In the first six months of life, he was often hospita-
lized (once a month) for wheezing, bronchiolitis, respira-
tory insufficiency (without hypercapnia) with respiratory
rate over 100/min requiring CPAP support, recurrent
bronchopneumonia, chronic cough. Bronchial secretions
microbiology revealed at different times the presence of
opportunistic agents as: Serratia Marcescens, Klebsiella
Pneumoniae, Acinetobacter baumannii. Staphilococcus
Aureus and Pseudomonas Aeruginosa (PA) responsible
for exacerbations. These were treated with intravenous
antibiotics and continuous aerosol therapy with tobra-
micin since the isolation of PA [10].
To avoid strangulation, cryptorchidism and inguinal her-
nias were surgically treated at three months and during
surgery bilateral agenesis of vasa deferentes was noted.
Also failure to thrive was evident (W/L was still dee-
ply < 3
rd centile). Although low weight and short length
might be due both to CF and syndrome, the most evi-
dent reason for them was that the child could not ever
r e a c ha na d e q u a t ed a i l yc a l o r i ci n t a k ef o rt h ee a s yf a t i -
gue in suction (due to the hypotonia and high heart
rate) and the recurrence of respiratory infections leading
to accessional cough and repeated vomiting.
When the patient was 6 months old more aggressive
airway clearance management and nutritional pro-
gramme were decided.
Respiratory function was considerably affected by the
severe hypotonia and malnutrition, and the device (PEP-
mask) chosen for chest physiotherapy revealed its use-
lessness with any clearing of bronchial secretions.
We introduced the use of the new device Ez-PAP
(Easy Positive Airway Pressure), which while maintain-
ing a positive pressure during the all breathing cycle by
high air or oxygen flows, may improve secretion clear-
ance [11]. The Ez-PAP device was used for 3 minutes
four times a day, followed by assisted cough. Its use
started during hospitalization, when safety and tolerabil-
ity were careful checked, and then home prescribed,
thank to the home oxygen flow availability. Its use did
not cause any fatigue for the baby, who complied well
to the device, showing improving respiratory pattern
and ameliorated chest x-ray images.
Figure 1 The patient’s usual face.
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Page 2 of 6Percutaneous endoscopic gastrostomy (PEG) was cho-
sen to provide adequate caloric intake (140 cal/kg/day),
given in five daily meals plus nocturnal supplementation
with a hydrolyzed diet and MCT. In the same time gas-
tro-oesophageal reflux disease (GORD) was diagnosed
and its treatment started and is still ongoing. Pancreatic
enzymes were given before each meal and at start and
in the middle of nocturnal supplementation, at doses
able to correct steatorrhea.
In Figure 2 the catch up curves of weight and length
are shown (arrows indicate when enteral nutrition started
and final length and weight at 24 months) leading to the
3-10
th centile for weight and on the 10-25
th centile for
length at 18 and 24 months (W/L 10-25
th centile).
Figure 2 The patient’s growth chart.
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Page 3 of 6After the Ez-PAP device was introduced and gastro-
stomy (GS) allowed the adequate caloric intake, a signif-
icant improvement in clinical condition was evident,
with only one more hospitalization till two years.
Daily neuromuscular physiotherapy was also per-
formed. The child was able to sit up unaided at 12
months, started assisted stand-up position at 18 months
(Figure 3) and assisted walking at 24 months.
At 24 months a swallowing study was performed with
normal results. Oral feeding was encouraged while main-
taining enteral supplementation by GS to reach adequate
caloric intake. Speech therapy was started to improve swal-
lowing and speech. Oxygen therapy was no longer needed.
A syndrome based follow-up was also started. Auxo-
endocrinologic, oculist (showing hypermetropia), ENT,
audiologist, orthopaedic, cardiologic (proving reduction
of pulmonary hypertension), immunologic (IgA defi-
ciency was detected), and neuropsychiatric evaluations
(assessing the cognitive delay) evaluations, were all regu-
larly scheduled. Cerebral MRI has not yet been per-
formed for its high anaesthesiologic risk.
Discussion
This case report underlies how two co-existing diseases
usually complicate each other’s clinical symptoms. Cystic
Fibrosis and 18q distal deletion syndrome were found
together in a patient and their clinical consequences have
been described for the first time in this case report.
The 18q- syndrome is determined by the terminal dele-
tion of the chromosome 18q arm. The length of the dele-
tion can vary from patient to patient, the commonest
involved bands being 18q21-qter. First described in 1964
by DeGrouchy et al., [12] the syndrome attributes several
distinctive features: short stature, hypotonia, mental retar-
dation, delayed developmental milestones, mid-face hypo-
plasia, “carp-like” mouth, palatal abnormalities, tapered
digits, proximal thumbs, hearing impairment, genitourin-
ary malformations (cryptorchidism, labra maiora absent)
and umbilical and inguinal hernia [MIM #601808]. Immu-
noglobulin A and M deficiencies [13,14] have also been
described. Ocular anomalies such as strabismus, anterior
optic segment malformations, nystagmus and myopia have
also been reported in several patients [15,16]. A variety of
neurological malformations and disorders are also part of
the syndrome: myelination disturbances, absent corpus
callosus, holoprosencephaly, seizures and EEG pattern
anomalies and psychiatric disorders (Rett syndrome, aut-
ism, depression, anxiety, mania, psychosis) [17-20].
As regard the correct diagnosis, our patient’sc a s eh i s -
tory underlines the importance of neonatal screening,
that may allow early detection of CF in infants whose
co-morbidities would otherwise dramatically delay the
diagnosis. Up to now, however, it is not performed by
all Italian Regions, and in 2009, 22% of newborn Italian
population did not undergo a CF neonatal screening
(report of the Italian Society for the Study of Inherited
Metabolic Diseases and Newborn Screening, 2010).
Thus in Regions where it is not performed, in all infants
with poor growth, and/or recurrent respiratory infec-
tions, it is mandatory to exclude the CF disease.
Our patient’s CF depending life prognosis and his
quality of life was worsened by syndrome symptoms.
Mental retardation was another complicating feature:
self-care and daily home therapy will require continuous
domestic and hospital surveillance.
Muscular hypotonia made the application of usual
chest physiotherapy device to our patient impossible.
Recently, in order to improve mucociliary clearance and
lung expansion, a new device called EzPAP has been
proposed [11]. It produces a positive airway pressure
throughout the breathing cycle via flow from an air or
oxygen flow meter and flow amplification. It is used for
atelectasis prevention and treatment and up to now the
major experience is on the treatment of postsurgery
atelectasis in adults [21]. The use of this device in our
patient prevented subsequent respiratory infections
without fatiguing the patient, given that no respiratory
muscle force is required. No information is currently
available on Ez-PAP use in children or CF patients. A
preliminary experience shows the device might be a
solution for removing bronchial secretions in selected
patients [22].
Figure 3 The patient at 18 months.
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Page 4 of 6GS for enteral nutrition is commonly used for CF and
patients suffering from neuromuscular disorders and
disability [23] as well as CF patients needing adequate
nutritional support. Our patient presented all the clinical
criteria for starting a chronic enteral nutrition supple-
mentation, which showed its usefulness in allowing a
normal growth pattern.
Conclusion
Several factors together have contribute to improve our
patient’s clinical condition: a better nutritional status, the
continuous use of antibiotics, therapy of GORD and the
use of the new device, all reduced the recurrence of
respiratory exacerbations and the need of hospitalizations.
Our patient’s history stresses the importance of being
ready to face clinical conditions which can be severely
complicated by co-existing diseases or genetic syn-
dromes and how this goal can be achieved through a
multi-disciplinary team of experts.
It is imperative to understand all therapeutic choices
available for CF patients and the need to share all treat-
ment chosen for CF patients with associated severe dis-
ease. These “brave” choices can improve treatment for
patients with CF alone. The same practice could be
helpful when facing to clinical conditions different from
CF, but leading to similar conditions, as malnutrition
and recurrent respiratory infections by bacteria as Pseu-
domonas aeruginosa, that are commonly seen in neu-
ropsychiatric clinics: the use of gastrostomy, chest
therapy and standard CF antibiotic protocols against
opportunistic agents may be used with positive outcome
and prognosis improvement also in these patients.
F i n a l l y ,t h ew o r ko fam u l t i d i s ciplinary cystic fibrosis
therapeutic team is mandatory to improve the treatment
of such severe and complicated clinical cases.
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